English / Japanese

TOKIWA-Bio is a gene-cell therapy and regenerative medicine product development company which has developed Stealth RNA Vector(SRV) an innovative technology of gene expression system. The SRV is the world-first RNA vector stabilized in cytoplasm and capable to install at least 10 genes on single vector.

Company Description

TOKIWA-Bio Inc. was founded in December 2014 based on an innovative discovery by The National Institute of Advanced Industrial Science and Technology (AIST). A company was authorized as one of “AIST Start-ups” in March 2015. A company specialize in R&D and practical application of gene-cell therapies, development of vectors of direct reprograming of cells for regenerative medicine, and biologics manufacture that can make the cost and process reduction.

We are developing a pipeline of stealth RNA vector (SRV)-based gene-cell therapies both internally and through multiple collaborations. We are advancing a broad pipeline of innovative gene therapies, initially focused on treatments for rare diseases, but through our collaborations and the strategic partnership we have to develop gene therapies for hemophilia and ischaemic disease, we have made the next step towards developing gene therapies targeting cancer and chronic diseases that affect larger populations. At present, we are engaged in development of device which can automatically establish iPS cells from blood monocyte and T-iPS cells from rare T cells in patients with cancer. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL).

Company Profile

Company name TOKIWA-Bio Inc.
Founded December 22, 2014, ("AIST Certified Venture" in March, 2015)
Capital Capital 100,000,000 yen
Address Headquarter:G-4 Tsukuba-TCI 2-1-6 Sengen, Tsukuba-shi, Ibaraki 305-0047 Japan ⇨Map
AIST Laboratory:1-1-1 Higashi, Central 5, Tsukuba-shi, Ibaraki 305-8565 Japan ⇨Map
TEL & FAX:029-893-6040
Delegates Masaharu Matsuzaki (President & CEO)
Number of Employees 5
Main business fields 1. R&D, manufacturing and sales of drugs related to regenerative medicine for gene therapy
2. R&D, manufacture and development of biopharmaceuticals, antibody drugs, etc.
3. R&D, manufacture and sales of research reagents


By developing the Japan-origin Stealth RNA Vector (SRV) technology in the advanced medical field, we will contribute to the advancement of gene-therapy medicine and keep up the competitiveness as well in the field of regenerative medicine in Japan.
By combining regenerative medicine and stem cell technology accumulated in Japan with the Stealth RNA Vector (SRV), as a Japanese venture company our goal for business development is contributing to the world.
Contributing as a fair, sincere and trustworthy member of the society with ambition and honesty to pursue and to create businesses that are useful for the society.